Neowise Biotechnology

Executive Summary

Neowise Biotechnology is a pioneering Chinese biotech company focused on developing TCR-T cell therapies for solid tumors, leveraging its proprietary CAST® high-throughput screening platform to identify natural T cell receptors (TCRs) targeting tumor antigens. Founded in 2020 and headquartered in Suzhou, the company has rapidly advanced multiple programs into Phase I clinical trials, supported by $300 million in funding. Its core technology addresses key limitations of CAR-T therapies in solid tumors, such as antigen heterogeneity and immunosuppressive microenvironments, by harnessing the natural sensitivity and specificity of TCRs. Neowise's pipeline targets prevalent cancers including hepatocellular carcinoma and non-small cell lung cancer, positioning it as a leader in the emerging TCR-T space in China. With a strong scientific foundation and substantial financial backing, the company is poised to deliver proof-of-concept data that could validate its platform and attract strategic partnerships.

Upcoming Catalysts (preview)

• Q3 2026Initial Phase I data readout for lead candidate (NW-101) targeting AFP-positive liver cancer30% success
• Q1 2027IND filing for second TCR-T program targeting solid tumors50% success